Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma Models

2 Nov 2022

Abstract excerpt

PURPOSE: PAX-fusion negative rhabdomyosarcoma (FN RMS) is driven by alterations in the RAS/MAP kinase pathway and is partially responsive to MEK inhibition. Overexpression of IGF1R and its ligands is also observed in FN RMS. Preclinical and clinical studies have suggested that IGF1R is itself an important target in FN RMS. Our previous studies revealed preclinical efficacy of the MEK1/2 inhibitor, trametinib, and...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Lung Cancer Treatments and Mutations
Share to PI3K/AKT/mTOR signaling in cancer
Share to Sarcoma Diagnosis and Treatment

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36322002
DOI: 10.1158/1078-0432.ccr-22-1646

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Combination of Trametinib and Ganitumab is Effective in RAS-Mutated PAX-Fusion Negative Rhabdomyosarcoma ModelsPMID 36322002Read ↗

Sensitization to Ionizing Radiation by MEK inhibition is Dependent on SNAI2 in Fusion-negative RhabdomyosarcomaSemantic proximity Read ↗

Efficacy of the MEK1/2 inhibitor trametinib in combination with clinically-investigated γ-secretase inhibitors in rhabdomyosarcomaSemantic proximity Read ↗

Dual Targeting of MAPK Signaling and Senescence-Associated Survival Pathways Overcomes Vincristine Resistance in Fusion-Negative RhabdomyosarcomaSemantic proximity Read ↗

Functional screening of FGFR4-driven tumorigenesis identifies PI3K/mTOR inhibition as a therapeutic strategy in rhabdomyosarcoma.Semantic proximity Read ↗

Cetuximab promotes anticancer drug toxicity in rhabdomyosarcomas with EGFR amplification in vitro.Semantic proximity Read ↗

Targeting the IGF1 axis in cancer proliferationSemantic proximity Read ↗

MEK inhibition causes BIM stabilization and increased sensitivity to BCL-2 family member inhibitors in RAS-MAPK-mutated neuroblastomaSemantic proximity Read ↗

Synergistic Antitumor Activity of Talazoparib and Temozolomide in Malignant Rhabdoid TumorsSemantic proximity Read ↗

A parallel-arm phase I trial of the humanised anti-IGF-1R antibody dalotuzumab in combination with the AKT inhibitor MK-2206, the mTOR inhibitor ridaforolimus, or the NOTCH inhibitor MK-0752, in patients with advanced solid tumoursSemantic proximity Read ↗

Dynamic and Nuclear Expression of PDGFRα and IGF-1R in Alveolar RhabdomyosarcomaSemantic proximity Read ↗

Preclinical Therapeutic Synergy of MEK1/2 and CDK4/6 Inhibition in NeuroblastomaSemantic proximity Read ↗

Combined targeting of MEK and the glucocorticoid receptor for the treatment of RAS-mutant multiple myeloma.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.